Market Cap 1.84B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 11,977,200
Avg Vol 7,961,004
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 89%
Beta 1.18
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Jun. 26 at 7:35 AM
$ABCL This is insane short interest continues to increase now sitting close to 23% and about 48,000,000 million short shares. What are they thinking…? They’re obviously not! This does not bode well for the shorts currently underwater and are borrowing more short shares on margin. This doesn’t end well imo for them. Short Faces will be melted soon.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 5:15 AM
$ABCL It would vault AbCellera out of small-cap biotech territory into a major large-cap biopharmaceutical player, with its stock trading between $90.05 and $144.08 per share.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 5:13 AM
$ABCL If both ABCL635 (hot flashes) and ABCL575 (eczema) achieve full clinical and commercial success, AbCellera's total peak annual internal product revenue would reach an estimated $5.5 billion.This dual-success scenario would trigger a massive structural re-rating by WS.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 1:38 AM
$ABCL Good volume for a long base breakout.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 12:02 AM
$ABCL If it doesn't fail this breakout I suspect there will be strength and maybe fast volatile upside, especially in Q3. The chart looks good and I think this could be a favourite in biotech in general- if we see further rotation into the sector. $75+/share?
1 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 25 at 11:59 PM
$ABCL I don't see this stopping till $8
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 25 at 11:53 PM
$ABCL $ABCL - room to 7.7
0 · Reply
JennyRowes
JennyRowes Jun. 25 at 11:42 PM
$ABCL 666, the sign of the beast!
2 · Reply
raccoonblackbear
raccoonblackbear Jun. 25 at 8:25 PM
$ABCL it's official... After 5 years of being underwater with this company, I have finally ended the day green on my FULL position. We're not out of the shark infested waters yet but man does it feel good to be floating on a raft. To all fellow longs, you know who you are... If your day still hasn't come yet... Get ready, the warship is coming
5 · Reply
Ckkung71
Ckkung71 Jun. 25 at 7:47 PM
$ABCL Let the battle begin… last 10 min..😂
0 · Reply
Latest News on ABCL
AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 20 days ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 6 weeks ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 7 weeks ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 2 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 4 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 4 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 5 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 10 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 10 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 11 months ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


Stocktradesmoon
Stocktradesmoon Jun. 26 at 7:35 AM
$ABCL This is insane short interest continues to increase now sitting close to 23% and about 48,000,000 million short shares. What are they thinking…? They’re obviously not! This does not bode well for the shorts currently underwater and are borrowing more short shares on margin. This doesn’t end well imo for them. Short Faces will be melted soon.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 5:15 AM
$ABCL It would vault AbCellera out of small-cap biotech territory into a major large-cap biopharmaceutical player, with its stock trading between $90.05 and $144.08 per share.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 5:13 AM
$ABCL If both ABCL635 (hot flashes) and ABCL575 (eczema) achieve full clinical and commercial success, AbCellera's total peak annual internal product revenue would reach an estimated $5.5 billion.This dual-success scenario would trigger a massive structural re-rating by WS.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 1:38 AM
$ABCL Good volume for a long base breakout.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 26 at 12:02 AM
$ABCL If it doesn't fail this breakout I suspect there will be strength and maybe fast volatile upside, especially in Q3. The chart looks good and I think this could be a favourite in biotech in general- if we see further rotation into the sector. $75+/share?
1 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 25 at 11:59 PM
$ABCL I don't see this stopping till $8
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 25 at 11:53 PM
$ABCL $ABCL - room to 7.7
0 · Reply
JennyRowes
JennyRowes Jun. 25 at 11:42 PM
$ABCL 666, the sign of the beast!
2 · Reply
raccoonblackbear
raccoonblackbear Jun. 25 at 8:25 PM
$ABCL it's official... After 5 years of being underwater with this company, I have finally ended the day green on my FULL position. We're not out of the shark infested waters yet but man does it feel good to be floating on a raft. To all fellow longs, you know who you are... If your day still hasn't come yet... Get ready, the warship is coming
5 · Reply
Ckkung71
Ckkung71 Jun. 25 at 7:47 PM
$ABCL Let the battle begin… last 10 min..😂
0 · Reply
bonecrack_benny
bonecrack_benny Jun. 25 at 7:41 PM
$ABCL we will fight until the end
0 · Reply
8008track
8008track Jun. 25 at 6:50 PM
$ABCL one day this might have a couple of zeroes attached to it. And trust me, I’ll be there smiling back on today.
1 · Reply
Arnoldsens
Arnoldsens Jun. 25 at 5:53 PM
$ABCL Shorters will knock down 52 week highs. Once they're out of the way it will be gametime once again.
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jun. 25 at 5:16 PM
$ABCL 8 inbound. . .
0 · Reply
DeMampCamp
DeMampCamp Jun. 25 at 5:04 PM
$ABCL Building a nice little base here in the mid $6.60S let's see what happens in the afternoon!
0 · Reply
NJgolfer
NJgolfer Jun. 25 at 4:06 PM
$ABCL up almost 50% since I called out the weekly but signal. Great position to be in with cost basis at $2.59 🚀🧑‍🚀
0 · Reply
tradersunion353
tradersunion353 Jun. 25 at 4:01 PM
$ABCL Need to stay above 8 soon ABCL you have not been perofrming for last 5 years.. now time to reward your investors/... fast
0 · Reply
tranq19
tranq19 Jun. 25 at 4:01 PM
$ABCL another 500k share buy at 11:30
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jun. 25 at 3:54 PM
0 · Reply
ra1980
ra1980 Jun. 25 at 3:35 PM
$ABCL i hold it since 2023 and closed it at 6.45$
2 · Reply
KUMO2026
KUMO2026 Jun. 25 at 3:33 PM
$ABCL break out
0 · Reply
Lolichocho
Lolichocho Jun. 25 at 3:32 PM
$ABCL that took less than two hours. This will be a triple digit stock in a few years.
0 · Reply